Chief Business Officer Corrine Savill Sells 40,000 Shares of Cullinan Oncology Inc
Corrine Savill, Chief Business Officer of Cullinan Oncology Inc (NASDAQ:CGEM), has sold 40,000 shares of the company on February 1, 2024, according to a recent SEC Filing. The transaction was executed at a price of $16.18 per share, resulting in a total value of $647,200.
Cullinan Oncology Inc is a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies. The company aims to address the unmet medical needs of cancer patients by applying a broad array of cancer therapies such as small molecules, biologics, and immuno-oncology approaches.
Over the past year, the insider has sold a total of 120,000 shares of Cullinan Oncology Inc and has not made any purchases of the stock. The recent sale by the insider is part of a series of transactions that have taken place over the last year.
The insider transaction history for Cullinan Oncology Inc reveals a pattern of insider selling activity. In the past year, there have been no insider buys recorded, while there have been 41 insider sells. This trend is often scrutinized by investors as insider selling can sometimes provide insights into potential future stock performance.
On the date of the insider's recent sale, shares of Cullinan Oncology Inc were trading at $16.18, giving the company a market capitalization of approximately $759.356 million.
Investors and analysts often monitor insider transactions as part of their due diligence process, as these transactions can provide valuable insights into insider sentiment and potential future stock movements. However, it is important to consider a wide range of factors when evaluating the implications of insider trading activity.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
